Pituitary growth hormone is a polypeptide molecule with a wide range of effects on protein, lipid, and carbohydrate metabolism (Korner, 1961; Raben, 1962; Finkel, 1962; Sirek and Sirek, 1964; Knobil and Hotchkiss, 1964 Ferrier, 1960; Lipsett, Bergenstal and Dhyse, 1961; Prader and Illig, 1962; Raben, 1962; Vest and Girard, 1962; Aarskog, 1963; Daughaday and Parker, 1963; Francois, Frederich, Bertrand, Gilly and Morelon-Bachelot, 1963; Trafford, Lifficrap and Lessof, 1963; Tanner, 1963b) Bryan (1960) , has disappointed most workers. We put an enormous effort into it and were finally forced to give up (
amount of HGH available, by our limited knowledge of the metabolic effect of HGH and its own turnover and metabolic fate, and by the difficulty of measuring HGH in biological fluids.
We have used HGH during the past four years and report here (I) some results of a standardized metabolic HGH test in dwarfs and its diagnostic and prognostic importance, (2) the growth effect of prolonged HGH therapy in a dosage that we believe to be in or near the physiological range, and (3) the clinical, metabolic, and immunological findings in patients who have developed antibodies against HGH. Before presenting our findings it seems appropriate to make a few remarks about the diagnosis of growth hormone deficiency.
Diagosis of Growth Hormone Deficiency and of Hypopituitary Dwarfism
We consider as hypopituitary those dwarfs whose growth and bone maturation are markedly retarded, who respond insufficiently to insulin-induced hypoglycaemia, and who show evidence of secondary insufficiency of the thyroid and/or the adrenal cortex.
It is still difficult to establish direct proof of growth hormone deficiency. Easy and reliable methods for measuring growth hormone in plasma and in urine are not yet available. The immuno-assay based on haemagglutination inhibition, originally proposed by Read and Bryan (1960) , has disappointed most workers. We put an enormous effort into it and were finally forced to give up (Szeky, Hollander, and Prader, 1961) . The newer radio-immuno-assay, introduced by Hunter and Greenwood (1962) and by others (Utiger, Parker, and Glick, Roth, Yalow, and Berson, 1963; Utiger, 1964; Touber, Maingay, and de Ruyter, 1964) , holds great promise. However, it seems that even the normal fasting subject may have growth hormone levels of nearly zero. Since hypoglycaemia is followed by a marked increase of the plasma growth hormone level (Roth, Glick, Yalow, and Hunter and Greenwood, 1964) , it seems likely that the increase of the plasma growth hormone level, induced by insulin and measured by the new radio-immuno-assay, will become the ideal test to estimate maximal growth hormone secretion. We still know very little about the urinary excretion of growth hormone (Salinas, Monckeberg, and Beas, 1963; Geller and Loh, 1963) (Simpson, Asling, and Evans, 1950; Desaulles and Krzhenb0hl, 1962) as well as in clinical experience (Prader and Illig, 1962; van The available information on the normal HGH plasma level and the HGH turnoverrate, which makes us believe that our dosage is in or somewhat below the physiological range, is as follows. As Parker, Utiger, and Daughaday (1962) , Roth et al. (1963) , HunterandGreenwood(1964 ),andUtiger(1964 The patient is put on an individual but rigidly constant diet containing 1 -3-2 -6 g. protein per kg. Any previous endocrine therapy is continued or had been stopped two to three months before the test. Urine is collected for daily determination of N and other constituents. Faeces are not collected. After a control period of at least 5 days the patient is given HGH daily for 5 to 6 days. Before and at the end of the HGH period plasma urea and other plasma constituents are determined and an intravenous insulin tolerance test with 4 units m.2 is performed.
We have performed this test in 12 hypopituitary dwarfs; 4 children with normal stature and 7 children with non-hypopituitary dwarfism served as controls.
The most interesting results are those of N excretion and of the insulin tolerance test. The decrease in daily urinary N excretion during HGH therapy is virtually identical with the increase in N retention, since faecal N is hardly affected. As expected the increase of N retention, expressed in mg. 'kg. or as percentage ofpre-treatment N excretion (Metcalf and Greene, 1963) , is much higher in the group with hypopituitary dwarfism than in the control group (Fig. 1 ). There is in fact hardly any overlap between the two groups. The absolute values are remarkably high and would decrease if the HGH treatment were continued.
We have similarly studied the effect of HGH on the excretion of creatine, calcium, and x-amino N. In contrast to the marked difference in N excretion in the two groups studied we did not find a significant difference in the creatine, calcium, and x-amino N excretion in the two groups. As is usually seen with HGH therapy, the urinary creatine values dropped if they were high and the calcium excretion increased in both groups. Among the effects of HGH studied, N retention is appar nrtly the only one that is clearly dependent on endogenous HGH secretion.
We feel that this controlled study confirms what was suggested by recent studies of Lipsett et al. (1961) and of Daughaday and Parker (1963) , namely that HGH causes a greater N retention in individuals deficient in growth hormone than in individuals with normal growth hormone production. We feel also that this test is a valuable aid in the diagnosis of growth hormone deficiency. Since growth is based on N retention the test should enable one to predict which patients will show a good growth response to prolonged treatment with HGH in physiological dosage. Such a prediction is important and helpful as long as there is so little HGH available. The N retention caused by HGH is accompanied by a decrease in blood urea which also is more marked in the hypopituitary dwarfs than in the controls (Fig. 2) . The blood a-amino N, which usually decreases under HGH treatment, showed an increase in most of the hypopituitary patients examined (Fig. 2) .
Unresponsiveness to insulin-induced hypoglycaemia which is so typical of hypopituitary dwarfs is usually found to be fully corrected when the insulin tolerance test is repeated at the end of the HGH test (Fig. 3) Daughaday and Parker (1963) , though we realize that the measuring error and seasonal growth variation make it difficult to evaluate growth response in such a short period. However, we decided not to await further confirmation and to stop the experinment in order to save the hormone for our susceptible hypopituitary patients.
Nine hypopituitary dwarfs, who had all shown a high N retention in the HGH test, were treated for a period between nine months and three years. In most of them the previous treatment with thyroid and/or corticoids and/or anabolic steroids was continued. Contrary to expectations only 6 of them showed an unequivocal growth acceleration. Fig. 4 increased his growth rate to 9-6 cm. a year during the first few months of therapy, and that it dropped later under the continued HGH therapy to about 4 -6 cm. a year. When HGH therapy was interrupted, growth decreased again to the original rate of less than 1 cm. a year and increased to 4 cm. a year when HGH treatment was taken up for the second time. Fig. 8 , from the same patient, is a conventional development chart showing height-age (Heimendinger, 1958) , weight-age (Heimendinger, 1958) , and bone-age (Tanner, Whitehouse, and Healy, 1962) .
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We still use this type of chart to evaluate and to demonstrate simultaneously the effect of a growthpromoting treatment on growth, on weight gain, and on skeletal maturation. Tanner (1962) has criticized this type of chart and has good reasons to do so. However, the chart still has its value if one is aware that in the normal subject bone-age will by definition always reach the top of the chart while height-and weight-age will reach variable levels depending on genetic and environmental influences. In our patients the chart clearly demonstrates that skeletal maturation, which hardly moved before HGH was given, accelerated under HGH treatment and was faster than growth and weight gain in spite of the fact that the dosage of anabolic steroids was much smaller than before. We have seen a similar acceleration of bone-age in all 5 hypopituitary patients whom we have treated successfully for more than nine months with a combination of HGH and thyroid in small doses and in some patients also cortisone and anabolic steroids. Fig. 9 is again a conventional growth chart from a girl with idiopathic hypopituitary dwarfism. In this patient thyroid function is probably normal. At the age of 5 to 6 her growth was much accelerated by large amounts of anabolic steroids and small doses of thyroid. With thyroid alone in a physiological dosage growth slowed down. At the age of 8 years HGH as the only therapy was started and very successfully continued for the next 2 years.
The growth rate is again better analysed in a growth velocity chart (Fig. 10) . Before therapy the growth rate is far below average, about 2 cm. a year. With anabolic steroids it is about 8 cm. a year or just above average. With thyroid alone it is again below average but still better than without any treatment. Growth hormone accelerated the growth rate to 10 cm. during the first year and to about 8 cm. during the second year. This chart is a beautiful demonstration of the growth-promoting effect of the two anabolic hormones, the anabolic steroids on one hand and HGH on the other hand.
The development chart of this patient (Fig. 11) is most interesting. It shows the well-known fact that anabolic steroids accelerate bone maturation more than growth, whereas HGH alone appears to accelerate growth more than bone maturation.
Acquired HGH resistance and HGH antibodies After these examples of successfully treated patients we have to analyse our 3 growth-resistant hypopituitary dwarfs (Prader, Szeky, Wagner, Illig, Touber, and Maingay, 1964) . These 3 patients all developed high titres of specific HGH antibodies during the first few months of treatment. The Post. Pit. metabolic and growth effect of HGH was suppressed. The other 6 patients, some of them treated for a much longer period, developed no or only low titres of HGH antibodies which did not interfere with the HGH effect on growth and metabolism.
Our group in Zurich and Dr. Touber and Dr. Maingay in Amsterdam* demonstrated the development of these antibodies and their specificity by two different methods. One is the haemagglutination method (Szeky, Hissig, and Prader, 1962) and the other the radio-immuno-assay method I i which apparently did not suppress the HGH effect on metabolism and growth.
We do not yet know why 3 out of our 9 patients developed HGH antibodies with such a disastrous clinical result. It could be that these 3 patients have never produced any HGH at all and have, therefore, no immunological tolerance for HGH, whereas the 6 other patients secrete small but insufficient amounts of HGH and have, therefore, a normal immunological tolerance for it.
The importance of our observation about HGH antibodies is twofold. As doctors we deplore this unexpected and disappointing complication of an enthusiastically welcomed new type of treatment. As scientists we note with interest that man is able to develop antibodies against a homologous protein hormone, which suppress the physiological effect of this hormone.
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